Study/Projects by Year (2019)

Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)

Post Date: 
2019-12-30
Learn more about this effort to foster development of long-lasting therapies for illnesses that require taking medications long-term

Inflammasome Genetics and Tuberculosis Treatment Outcomes

Post Date: 
2019-11-07
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is a Co-PI on this study. STUDY DESIGN We will conduct a retrospective case-cohort study nested within the CTRIUMPH and EDOTS cohorts to address our study objectives. This will enable us to measure the association of polymorphisms with multiple clinical outcomes simultaneously and...

A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of ID93 + GLA-SE Vaccine Administered to HIV-Negative Patients at 3 Time Points During Multidrug Therapy for Drug Susceptible Pulmonary TB

Post Date: 
2019-10-28
   |   
Clinical Sites: 
Vidya Mave is PI of this HIV vaccine trial. BACKGOUND: Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (Mtb). TB is one of the leading causes of morbidity and mortality around the world with an estimated 10 million cases of active TB each year and 1.6...

Evaluation of a Urinary Biomarker Assay for Diagnosis and Test of Cure for Tuberculosis

Post Date: 
2019-09-09
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Jeff Tornheim is PI of this study. METHODS This study will make use of biorepository samples from the Cohort for TB Research by the Indo-US Medical Partnership (CTRIUMPh). CTRIUMPh, funded by the US NIH and Indian Department of Biotechnology, is an academic collaboration between Johns Hopkins...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB patients living with HIV compared with TB...

A5300B/I2003B: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx)

Post Date: 
2019-08-19
   |   
Countries: 
   |   
Clinical Sites: 
Dr. Amita Gupta is Protocol Co-chair for this multinational clinical trial. BACKGROUND The World Health Organization (WHO) estimates that there were 480,000 incident cases of MDR-TB globally in 2015. MDR-TB has been shown to be almost twice as common in TB patients living with HIV compared with TB...

Management of Multidrug-resistant Tuberculosis among ART Programs in Low- and Middle-income Countries within the Global IeDEA Network

Post Date: 
2019-07-22
Purpose The purpose of the IeDEA MDR-TB survey is to study the clinical management of HIV patients co-infected with MDR-TB or XDR-TB from the perspective of healthcare workers in ART programs participating in the IeDEA global cohort consortium. Specifically, we aim: to describe diagnostic, referral...

Visual Field Loss in HIV-Positive Patients of Non-Infectious HIV Retinopathy

Post Date: 
2019-06-02
   |   
Countries: 
   |   
Clinical Sites: 
New study will assess HIV+ patients and determine the prevalence of visual field loss due to noninfectious HIV retinopathy

Immune Correlates of LTBI in HIV-exposed Infants

Post Date: 
2019-04-29
   |   
Countries: 
About 2 billion people worldwide harbor asymptomatic latent TB infection (LTBI), activation of which results in progression to TB disease. In areas of high tuberculosis (TB) prevalence, infants and young children have a 3-fold higher risk of progression and death from TB at age < 5 years...

Hard-to-Reach Populations: Implications for Ending the AIDS Epidemic

Post Date: 
2019-04-25
   |   
Countries: 
The Rakai region in Uganda was the initial epicenter of the HIV epidemic in East Africa and continues to be a high burden area, with an HIV prevalence of ~13%. Through the open, population-based Rakai Community Cohort Study (RCCS), we reported that combination HIV prevention (CHP) decreased...

¡Sólo Se Vive Una Vez! (You Only Live Once)

Post Date: 
2019-04-02
   |   
Countries: 
When CFAR Scholar Dr. Kathleen Page began working at the Baltimore City Health Department (BCHD) STD/HIV clinic in 2006, she noticed a growing number of Spanish-speaking patients. Here at Hopkins, she also began receiving requests to see Latino patients who had been newly diagnosed with HIV, many of whom had already been infected for long periods of time. Dr. Page quickly realized we weren’t doing enough to bring prevention and testing programs to the Spanish-speaking population of Baltimore.

P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants “VESTED”

Post Date: 
2019-02-06
   |   
Countries: 
   |   
Clinical Sites: 
Full Title: P2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants “VESTED”: V irologic E fficacy and S afety of ART Combinations with T AF/TDF, E FV, and D...